Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Peptides derived from HIV-1 Vif: A non-substrate based novel type of HIV-1protease inhibitors
Autore:
Friedler, A; Blumenzweig, I; Baraz, L; Steinitz, M; Kotler, M; Gilon, C;
Indirizzi:
Hebrew Univ Jerusalem, Dept Organ Chem, IL-91904 Jerusalem, Israel Hebrew Univ Jerusalem Jerusalem Israel IL-91904 -91904 Jerusalem, Israel Hebrew,Univ Jerusalem, Hadassah Med Sch, Dept Mol Genet, IL-91010 Jerusalem Hebrew Univ Jerusalem Jerusalem Israel IL-91010 enet, IL-91010 Jerusalem Hebrewsrael Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91010 Jerusalem, I Hebrew Univ Jerusalem Jerusalem Israel IL-91010 l, IL-91010 Jerusalem, I
Titolo Testata:
JOURNAL OF MOLECULAR BIOLOGY
fascicolo: 1, volume: 287, anno: 1999,
pagine: 93 - 101
SICI:
0022-2836(19990319)287:1<93:PDFHVA>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; ACCESSORY PROTEINS; DESIGN;
Keywords:
HIV-1; aspartic protease inhibitor; Vif; peptide mapping; HIV-PR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Gilon, C Hebrew Univ Jerusalem, Dept Organ Chem, IL-91904 Jerusalem, Israel Hebrew Univ Jerusalem Jerusalem Israel IL-91904 rusalem, Israel
Citazione:
A. Friedler et al., "Peptides derived from HIV-1 Vif: A non-substrate based novel type of HIV-1protease inhibitors", J MOL BIOL, 287(1), 1999, pp. 93-101

Abstract

The retroviral protease (PR) is absolutely essential for completion of human immunodeficiency virus multiplication cycle, and cannot be replaced by any cellular function. Thus PR, like reverse transcriptase, is an ideal target for the development of anti-AIDS therapy. A large number of human immunodeficiency virus type-1 (HIV-1) PR inhibitors have been developed, and several are currently used as anti-AIDS drugs. These inhibitors are mainly based on the natural PR cleavage sites within the viral Gag and Gag-Pol precursors. The major difficulty encountered while using anti-HIV therapeutic agents in patients has been the rapid emergence of drug-resistant viral strains. Most of the mutations which convert the PR into inhibitor-resistant are located within the substrate binding subsites of the enzyme. Recently, it has been shown that the HIV-1 auxiliary protein Vif, and especially the N-terminal half of Vif (N'-Vif) specifically interacts with the viral PR and inhibits its activity. We now show that efficient inhibition of HIV-1 PR activity can be achieved using Vif-derived peptides. Based on the above model wehave performed peptide mapping of N'-Vif in order to find a small peptidiclead compound which inhibits PR activity. The screening revealed that peptides derived from two regions in Vif spanning from residues 30-65 and 78-98inhibit PR activity in vitro, specifically bind HIV-PR and inhibit HIV-1 production in vivo. Further mapping of these regions revealed the lead compounds Vif81-88 and Vif88-98. These peptides specifically inhibit and bind HIV-1 PR, but do not affect pepsin and rous sarcoma virus protease. In contrast to other known PR inhibitors, these peptides are not substrate-based andtheir sequences do not resemble the sequences of the natural PR substrates(cleavage sites). Moreover, the Vif-derived peptides themselves are not cleaved by HIV-1 PR. Conversion of the lead peptides into small backbone cyclic peptidomimetics is taking place nowadays in order to turn these lead compounds into metabolically stable selective novel type of HIV-PR non-substrate-based inhibitors. (C) 1999 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 13:33:16